A Model-Based Framework to Identify Optimal Administration Protocols for Immunotherapies in Castration-Resistance Prostate Cancer

SIMPLE SUMMARY: Although ipilimumab has been approved for the treatment of many types of cancer, most prostate cancer patients seem to not respond well to the therapy. Here, we mathematically investigate the clinical relevance of ipilimumab, as mono-therapy and in combination with the dendritic cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Coletti, Roberta, Pugliese, Andrea, Lunardi, Andrea, Caffo, Orazio, Marchetti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750226/
https://www.ncbi.nlm.nih.gov/pubmed/35008298
http://dx.doi.org/10.3390/cancers14010135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750226/
https://www.ncbi.nlm.nih.gov/pubmed/35008298
http://dx.doi.org/10.3390/cancers14010135

Ejemplares similares